Investors: Press Release
AVITA Wins Best Emerging Company Investor Relations Award
VALENCIA, Calif. and MELBOURNE, Australia, 2 June 2022— AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercialising a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, is pleased to announce that it has won the Australasian Investor Relations Association (AIRA) Award for Best Investor Relations by a Company in the S&P/ASX Emerging Companies Index.
In its 21st year, AIRA’s Best Practice Investor Relations Awards recognise industry leaders for their efforts in working openly and effectively with the professional investment community. Winners are determined by an independent survey of domestic and international buy and sell-side brokers and fund managers.
Accepting the award at the AIRA ceremony in Sydney last night, AVITA Chief Financial Officer, Michael Holder, said “We thank AIRA for its continued support for this award which recognises the significance of imparting our strategy, performance and, critically, the potential of our company to the investment community.”
The AIRA investor relations awards are considered to be the most prestigious investor relations awards in Australia and are sponsored by the Australian Securities Exchange.
ABOUT AVITA MEDICAL, INC.
AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the
areas of the patient requiring treatment.
AVITA Medical’s first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 10,000 patients globally reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.
In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe. To learn more, visit www.avitamedical.com.
FOR FURTHER INFORMATION: